Abstract
Results: Concentration of fecal calprotecin is: (1) statistically higher in stools taken from patients with ulcerative colitis than in stools of patients with functional bowel diseases, (2) statistically higher in stools collected from patients with Crohn’s disease than in stools of patients with functional bowel disorders, (3) statistically higher in stools acquired from patients with non-active inflammatory bowel disease than in stools of patients with functional bowel diseases. Conclusions: The results of the study suggest that testing calprotectin levels in stools can help to distinguish between functional and inflammatory bowel disease, as well as to differentiate between its active and non-active form.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
